Company news
Outlook Therapeutics, Inc. news in 2026
Outlook Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
October 9, 2026
Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion
October 6, 2026
Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
October 1, 2026
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
September 11, 2026
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
September 10, 2026
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
August 27, 2026
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
August 14, 2026
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
August 12, 2026
Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
August 12, 2026
Outlook Therapeutics Secures FDA Approval For LYTENAVA™
August 5, 2026
Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD
July 23, 2026
Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA as a Treatment for Wet AMD
June 17, 2026
Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD
June 16, 2026
Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
June 1, 2026
Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
May 28, 2026
Sapu Nano Unveils Progress in Deciparticle™ Nanomedicine Platform and AI-Driven Oncology Development at BIO 2026
May 28, 2026
Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
May 26, 2026
Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
May 15, 2026
Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
April 23, 2026
Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
April 21, 2026
Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
April 20, 2026
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA
April 6, 2026
Outlook Therapeutics Announces Closing of $5.0 Million Public Offering
March 24, 2026
Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering
March 23, 2026
Outlook Therapeutics Announces Proposed Public Offering
March 22, 2026
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note
March 15, 2026
Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)
March 4, 2026
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland
February 18, 2026
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
February 17, 2026
Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter
February 11, 2026
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development
January 6, 2026
Calls in 2026
Decks in 2026
- Q3 2026 Earnings Presentation
Earnings · 16 slides · Aug 14, 2026